The Dayton Clinical Oncology Program (DCOP) was incorporated in the State of Ohio in 1982 as a non-profit 501 C-3 corporation. A Consortium Agreement was established between DCOP, the Dayton Area hospitals (all except Children's Medical Center), and Wright State University (WSU). A governing board was established, and corporate bylaws were developed. Currently, DCOP has an elected Board of Trustees with Howard M. Gross, M.D., DCOP Principal Investigator, as Chairperson of the Board, Stuart Merl, M.D., Associate Principal Investigator, as Vice Chairperson, Sidney J. Pinkus, MBA, Chief Executive Officer of DCOP, as President of the Board, and 15 other Trustees representing the 13 member hospitals, WSU, and at-large community members of our service area. The Board meets quarterly to review budget reports and program activities. Since 1982, DCOP has successfully applied for and received funding from NCI as a CCOP. We are currently seeking continued funding through the fiscal year ending May 31, 2014. Our current staff includes 16 Oncology Research Nurses funded by our member hospitals, and 16 office staff funded by the grant, including directors for quality, regulatory, and prevention, quality coordinator, data coordinator, research manager, data managers, administrative assistant, research associates, and research coordinators. Our current active physician Co Investigators total 74, representing our 13 hospitals and various specialties including oncology, radiation therapy, urology, surgery, gynecology, pulmonary and gastroenterology. WSU has been providing personnel, payroll, and accounting services support through a sub-contracting relationship established on December 23, 2001, when the grant was transferred from former fiscal agent Kettering Medical Center to DCOP. DCOP has continued as the grantee organization since that date.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA035090-31S1
Application #
8850950
Study Section
Special Emphasis Panel (ZCA1-SRRB-Y (J1))
Program Officer
St Germain, Diane
Project Start
1983-09-15
Project End
2014-07-31
Budget Start
2014-06-01
Budget End
2014-07-31
Support Year
31
Fiscal Year
2014
Total Cost
$166,743
Indirect Cost
Name
Dayton Clinical Oncology Program
Department
Type
DUNS #
613819200
City
Dayton
State
OH
Country
United States
Zip Code
45420
Liu, Xiaonan; Li, Jing; Wu, Teresa et al. (2016) Patient Specific Characteristics Are an Important Factor That Determines the Risk of Acute Grade ≥ 2 Rectal Toxicity in Patients Treated for Prostate Cancer with IMRT and Daily Image Guidance Based on Implanted Gold Markers. OMICS J Radiol 5:
Park, Haeseong; Qin, Rui; Smith, Thomas J et al. (2015) North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes. Menopause 22:627-32
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O⁶-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Rule, William G; Foster, Nathan R; Meyers, Jeffrey P et al. (2015) Prophylactic cranial irradiation in elderly patients with small cell lung cancer: findings from a North Central Cancer Treatment Group pooled analysis. J Geriatr Oncol 6:119-26
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Yu, Evan Y; Li, Hongli; Higano, Celestia S et al. (2015) SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol 33:1601-8
Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-40

Showing the most recent 10 out of 196 publications